23andMe Investor Day Presentation Deck
CD96 was Identified as a Promising Anti-Cancer Drug Target with
23andMe's Proprietary Immune-Oncology (I/O) Genetic Signature
Immune and
autoimmune
phenotypes
Cancer
phenotypes
Identified novel immuno-oncology
signature around CTLA4
tonsillectomy -
t1d-
anti_tnf_alpha_or_dmards -
juvenile_t1d-
iqb.dry_skin_frequency -
iodine treatment_ever-
hypothyroidism -
hyperthyroidism -
hashimotos -
graves-
vitiligo-
iqb.dandruff frequency -
celiac HLA_all-
signed log(p)
psoriasis-
rheumatoid arthritis -
took meds_anti_tnf_alpha-
thyroid_removed -
immunodeficiency -
squamous_cell_carcinoma -
basal cell carcinoma -
actinic_keratosis -
_non_melanoma_skin_cancer-
ny_sk cancer
-10 -5 0 5 10
Genetic Variant in CTLA4 linked
with multiple phenotypes in the
23andMe database
CD96/CD226 pathway identified
as a checkpoint with our I/O
genetic signature
I/O genetic signature shows opposing effects
on autoimmune and cancer phenotypes
CD226 pathway
(includes CD96)
signed log(p)
Multiple
Autoimmune
Phenotypes
Multiple Cancer
Phenotypes
-10 -5 0 5 10
Copyright © 2022 23andMe, Inc.
23andMe
44View entire presentation